Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Nutex Health (NUTX) Research & Development (2019 - 2022)

Nutex Health's Research & Development history spans 4 years, with the latest figure at $73750.0 for Q1 2022.

  • For Q1 2022, Research & Development fell 3.87% year-over-year to $73750.0; the TTM value through Mar 2022 reached $282910.0, down 45.5%, while the annual FY2021 figure was $285880.0, 48.7% down from the prior year.
  • Research & Development for Q1 2022 was $73750.0 at Nutex Health, down from $77265.0 in the prior quarter.
  • Across five years, Research & Development topped out at $314255.0 in Q2 2020 and bottomed at $54296.0 in Q4 2020.
  • The 4-year median for Research & Development is $77265.0 (2021), against an average of $129614.6.
  • The largest YoY upside for Research & Development was 42.3% in 2021 against a maximum downside of 81.03% in 2021.
  • A 4-year view of Research & Development shows it stood at $196632.0 in 2019, then tumbled by 72.39% to $54296.0 in 2020, then soared by 42.3% to $77265.0 in 2021, then decreased by 4.55% to $73750.0 in 2022.
  • Per Business Quant, the three most recent readings for NUTX's Research & Development are $73750.0 (Q1 2022), $77265.0 (Q4 2021), and $72266.0 (Q3 2021).